Biopharma companies develop medicines, vaccines and advanced therapies to prevent, treat and manage disease. The sector spans drug discovery, clinical development, manufacturing and commercialisation across a wide range of therapeutic areas.
This category includes companies working on:
Browse 304 UK biopharma companies below.
Ovine polyclonal therapeutics developer and antivenom manufacturer
MicroPharm is a specialty pharmaceutical company developing and manufacturing ovine polyclonal antibody therapeutics for the treatment of acute toxic and infectious conditions. The company's MHRA-licensed facilities in West Wales produce a portfolio of clinical-grade antivenoms, including products acquired from Sanofi…
Neuroactive therapeutics through genetic engineering of fungi and plants
Empyrean Neuroscience is a biopharma company that uses genetic engineering of fungi and plants to develop small molecule therapeutics for neuropsychiatric and neurologic disorders. Using CRISPR/Cas9 and proprietary transformation technologies, the platform enables precise modulation of neuroactive compound production.…
AI-driven drug discovery targeting necrosis and age-related disease
LinkGevity is a preclinical-stage biotechnology company developing anti-necrotic therapeutics for age-related and degenerative diseases. Founded in 2023 and based at Babraham Research Campus, the company's proprietary Blueprint Theory of Ageing identifies necrosis as a key driver of biological decline, informing its…
Tumour-activated peptide drug conjugates for targeted oncology
Avacta Therapeutics is a clinical-stage biotechnology company developing peptide drug conjugates designed to deliver toxic chemotherapy payloads selectively within the tumour microenvironment. The company's delivery approach uses a short engineered peptide that masks the active payload until it is cleaved by…
Isoform-specific antibody therapeutics for vascular disease
IsomAb is a biotechnology company developing isoform-specific antibody therapeutics for serious vascular diseases. Its lead programme, ISM-001, targets VEGF-A165b, an anti-angiogenic splice isoform implicated in peripheral arterial disease and chronic limb-threatening ischaemia. The company uses a…
Oral thermostable vaccine platform for infectious diseases
iosBio is a biotechnology company developing thermostable oral vaccines using adenoviral vector delivery. Its platform protects vaccine vectors to survive stomach transit and release in the lower small intestine, inducing mucosal and systemic immunity without cold chain requirements or needle administration. The lead…
Rare and serious disease therapeutics with Cambridge R&D hub
Insmed is a US biopharmaceutical company with commercial-stage and late-pipeline products spanning respiratory, inflammatory and rare neurological diseases. Its Cambridge facility at Babraham Research Campus, established through the 2023 acquisition of Adrestia, leads drug discovery using the company's synthetic…
Small molecule therapies for keratin-related skin disorders
Mariposa Therapeutics is a Welsh preclinical biopharma company developing disease-modifying treatments for epidermolysis bullosa simplex and other keratin-related skin disorders. Its lead compound, MP5219, is a synthetic analogue of ajoene that activates surrogate keratin expression to compensate for the underlying…
Global biopharma with UK R&D hub in Hertfordshire
Roche Products is the UK pharmaceutical arm of F. Hoffmann-La Roche, headquartered at Welwyn Garden City in Hertfordshire. The site employs over 1,900 people and serves as a primary hub for early-stage drug discovery, clinical development, computational sciences, and commercial operations. The UK operation contributes…
AI-guided synthetic lethality drug discovery for oncology
Evariste is a drug discovery company developing small-molecule inhibitors of synthetic lethal targets in cancer. Its computational platform combines machine learning, multimodal biological data and molecular modelling to identify therapeutic targets, design candidate compounds and prioritise laboratory testing. The…
AI platform engineering molecular glue drugs for undruggable targets
Ternary Therapeutics is a preclinical-stage biotechnology company developing an AI-driven platform for the rational design of molecular glue therapeutics. Molecular glues are small molecules that induce proximity between two proteins, enabling targeted degradation or modulation of disease-driving targets that lack…
Yeast strain engineering platform for recombinant protein biomanufacturing
Phenotypeca is a synthetic biology company that engineers baker's yeast strains for the production of recombinant proteins, biosimilars, and vaccine antigens. Using proprietary quantitative trait loci technology, the company generates and screens large libraries of yeast variants to identify production strains with…
In vivo lentiviral CAR/TCR cell therapy platform for ovarian cancer
Akimbo Bio is an early-stage biotechnology company developing next-generation in vivo lentiviral vector technology for cell therapy. Its lead platform carries a dual CAR/TCR payload designed for direct in vivo delivery, with an initial focus on ovarian cancer. The technology uses intelligent receptor crosstalk, in…
Genomics platform developing RNA therapies for chronic liver disease
Ochre Bio is a biotechnology company developing RNA therapeutics for chronic liver disease using a platform built on large-scale human liver datasets. The platform integrates gene perturbation atlases, single-cell genomics from perfused donor livers, and machine learning to identify and validate disease-modifying drug…
Targeted nanoparticles for in vivo CAR-T and gene delivery
Deliver Biosciences is a biotechnology company developing targeted nanoparticle vectors for in vivo cell and gene therapies. Its delivery platform transports genetic payloads, including DNA and mRNA, into selected cell types using programmable targeting components. Its lead programme aims to engineer T cells inside…
Circadian hormone therapeutics for rare endocrine conditions
Neurocrine UK is the European operations of Neurocrine Biosciences, a Cardiff-headquartered specialty pharmaceutical company developing and commercialising hormone therapeutics for rare and chronic endocrine conditions. The company's scientific approach centres on circadian-based formulation technology, designed to…
Combinatorial stem cell screening platform for therapy development
Plasticell is a biotechnology company developing cell and gene therapies and enabling drug discovery through its proprietary platform. The technology uses bead-based combinatorial screening to test thousands of cell culture variable combinations in parallel, identifying optimised protocols for stem cell expansion,…
AAV gene therapies for rare and neurological diseases
Spur Therapeutics is a clinical-stage biotechnology company developing adeno-associated virus-based gene therapies for serious chronic diseases. Its lead programme is a Phase I/II gene therapy for Gaucher disease type 1, a rare lysosomal storage disorder. Further pipeline candidates target GBA1 Parkinson's disease and…
Precision oncology biotech targeting synthetic lethality in cancer
Tessellate Bio is a precision oncology company developing small molecule drugs that exploit synthetic lethality, the principle that certain genetic vulnerabilities in cancer cells can be targeted to selectively kill tumour cells. The company's lead programme targets the FANCM complex in cancers relying on Alternative…
Bispecific TCR therapies targeting HLA-Class II cancer antigens
Yellowstone Biosciences is a pre-clinical biotechnology company developing bispecific T-cell receptor therapies for oncology. The company targets a novel class of HLA Class II antigens expressed across multiple cancers, with an initial programme focused on acute myeloid leukaemia. Its approach is designed to…